#USA #Carlsbad #Tyra Biosciences #FGFR Biology #Dabogratinib

Tyra Biosciences Prices $400 Million Stock Offering

Introduction
On September 14, 2026, Tyra Biosciences, Inc. (Nasdaq: TYRA), a pioneering clinical-stage biotechnology firm based in Carlsbad, California, declared the pricing of its underwritten offering. The company focuses on advancing next-generation precision medicines specifically aimed at significant opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. This stock offering aims to raise approximately $400 million to propel the company's development initiatives.

Details of the Offering
Tyra's offering includes 9,079,000 shares of common stock priced at $22.03 per share. In addition, the company will offer pre-funded warrants for about 9,078,529 shares of common stock at a slightly lower cost of $22.029 per share. These warrants are available to specific investors and provide an alternative to purchasing common stock directly, allowing them to exercise their options at a nominal price. The overall proceeds from this offering, expected to close on September 15, 2026, will help fund multiple strategic areas vital for the company’s growth.

Use of Proceeds
The capital raised from this financing will be allocated toward various developmental undertakings, including the advancement of Tyra's flagship product, dabogratinib, which is currently being evaluated for treating low-grade upper tract urothelial carcinoma (LG-UTUC), intermediate-risk non-muscle invasive bladder cancer (IR NMIBC), and achondroplasia (ACH). Additional funding will support other preclinical studies, drug discovery efforts, operational financial needs, and general corporate purposes, thereby bolstering Tyra's position in the competitive biopharmaceutical landscape.

Underwriters and Investors
The joint book-running managers for this offering include notable names such as Jefferies, Guggenheim Securities, Cantor, Barclays, and William Blair. They will be joined by Wedbush PacGrow, Raymond James, and Oppenheimer & Co., acting as lead managers. The offering has attracted participation from both new and existing institutional investors, indicating strong confidence in Tyra’s strategic direction and product pipeline.

A Look Ahead
As the offering gears up to close, Tyra emphasizes the timely nature of these funds. The biotechnology landscape is increasingly competitive, and having adequate financial backing is crucial for executing on developmental timelines. Tyra’s use of proceeds will directly impact its ability to advance significant therapeutic candidates that target critical medical needs.

Understanding Tyra's Product Pipeline
Tyra's lead candidate, oral dabogratinib, is under development primarily to inhibit FGFR3 selectively, representing a potential first-in-class treatment option. Its continued research into specific oncology settings illustrates the company's commitment to enhancing patient outcomes through tailored therapeutic strategies. Alongside dabogratinib, the company is also working on TYRA-430 and TYRA-200, which target different FGFR biology aspects and are currently involved in advanced clinical studies for distinct cancer types.

Conclusion
The $400 million stock offering by Tyra Biosciences reflects the company’s robust growth strategy aimed at addressing urgent healthcare needs with precision medicines. With the closing date on the horizon, stakeholders remain focused on how these developments can influence Tyra’s future trajectory. The successful execution of this offering could catalyze further innovations within Tyra’s pipeline, potentially leading to significant advancements in cancer treatments and related genetic conditions.